Suppr超能文献

基于数据挖掘的48例新型冠状病毒肺炎重症监护病房患者中医用药规律研究

[Study on medication laws of traditional Chinese medicine of 48 patients with coronavirus disease 2019 in intensive care unit based on data mining].

作者信息

Liu Yuan, Mei Jianqiang, Chen Fenqiao, Yang Yaru

机构信息

Department of Intensive Care Unit, Hebei Traditional Chinese Medicine Hospital, Hebei University of Chinese Medicine, Shijiazhuang 050011, Hebei, China.

Department of Emergency, Hebei Traditional Chinese Medicine Hospital, Hebei University of Chinese Medicine, Shijiazhuang 050011, Hebei, China. Corresponding author: Mei Jianqiang, Email:

出版信息

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021 Oct;33(10):1175-1180. doi: 10.3760/cma.j.cn121430-20210826-01285.

Abstract

OBJECTIVE

To analyze the data of Chinese medicine prescriptions for the treatment of coronavirus disease 2019 (COVID-19) in Shijiazhuang City, Hebei Province, with a view to further guide the clinical use of Chinese medicine in the prevention and treatment of COVID-19.

METHODS

Forty-eight patients diagnosed with COVID-19 who were treated by critical care team of Hebei Traditional Chinese Medicine Hospital in the intensive care unit (ICU) of Hebei Chest Hospital (Hebei Provincial COVID-19 designated hospital) from January 7 to March 4, 2021, were enrolled in this study. The patients' gender, age, clinical classification, past history, and all Chinese medicine prescriptions for the first visit and follow-up visits during the hospitalization were collected. A database was established based on the Ancient and Modern Medical Records Cloud Platform (V2.2.1), and the methods of frequency analysis, correlation analysis, cluster analysis, and complex network analysis were used to analyze the prescriptions of traditional Chinese medicine.

RESULTS

Among the 48 patients with COVID-19, 20 were males and 28 were females; the average age was (62.4±13.7) years old. The patients' condition was generally severe, including 17 cases of common type, 25 cases of severe type, and 6 cases of critical type, most of whom were combined with hypertension, coronary heart disease, diabetes, chronic obstructive pulmonary disease and other basic illnesses. A total of 146 valid prescriptions were included, involving 59 prescriptions and 115 Chinese medicines. Frequency analysis of 146 prescriptions showed that the commonly used prescriptions for patients with COVID-19 were Qingfei Paidu decoction (30 times, 20.55%), Xuanbai Chengqi decoction (10 times, 6.85%), and Dayuan Yin (10 times, 6.85%). The common Chinese medicines were liquorice (80 times, 54.79%), tuckahoe (76 times, 52.05%), gypsum (70 times, 47.95%), bitter almond (70 times, 47.95%), ephedra (57 times, 39.04%), scutellaria (56 times, 38.36%), tangerine peel (53 times, 36.30%), patchouli (50 times, 34.25%), atractylodes macrocephala (50 times, 34.25%), and bupleurum (43 times, 29.45%). The main effects were clearing heat and detoxification (129 times), clearing heat-fire (129 times) and eliminating dampness and diuresis (110 times). The medicinal properties were mainly warm (509 times), flat (287 times), and cold (235 times). The medicinal tastes were mainly pungent (765 times), sweet (654 times), and bitter (626 times). The medicinal channel tropism were mainly lung (1 096 times), spleen (785 times), and stomach (687 times). The correlation analysis showed that there were 17 drug combinations in total, among which the top 3 drug pairs in support were bitter almond-gypsum (0.43), ephedra-bitter almond (0.38), tangerine peel-poria (0.36), and ephedra-gypsum (0.36). Cluster analysis showed that there were 3 groups of clustering formulas. The first group was ephedra, bitter almond, and gypsum. The second group was patchouli, tuckahoe, tangerine peel, and atractylodes macrocephala. The third group was scutellaria, licorice, immature orange fruit, oriental waterplantain rhizome, bupleurum, ginger, and cassia twig. The core drugs were composed of tuckahoe, bupleurum, tangerine peel, atractylodes macrocephala, patchouli, bitter almond, scutellaria, gypsum, ephedra, and licorice.

CONCLUSIONS

Middle-aged and elderly patients with COVID-19 are accompanied by Qi deficiency and internal invasion of toxins, and the pathogenesis evolves rapidly. Damp and turbid toxins often block the lungs and trap the spleen, leading to disorder of Qi movement, and even invaginate Ying and Xue, drain Yin and Yang. The treatment is based on removing turbidity and detoxification, and replenishing Qi and nourishing Yin are the principle treatments, so that the evil is eliminated and the Qi is restored.

摘要

目的

分析河北省石家庄市治疗新型冠状病毒肺炎(COVID-19)的中药方剂数据,以期进一步指导中医药在COVID-19防治中的临床应用。

方法

选取2021年1月7日至3月4日在河北省胸科医院(河北省COVID-19定点医院)重症监护病房(ICU)由河北省中医院重症团队治疗的48例确诊为COVID-19的患者纳入本研究。收集患者的性别、年龄、临床分型、既往史以及住院期间首次就诊和随访的所有中药方剂。基于古今医案云平台(V2.2.1)建立数据库,采用频数分析、相关性分析、聚类分析和复杂网络分析等方法对中药方剂进行分析。

结果

48例COVID-19患者中,男性20例,女性28例;平均年龄为(62.4±13.7)岁。患者病情普遍较重,其中普通型17例,重型25例,危重型6例,多数合并高血压、冠心病、糖尿病、慢性阻塞性肺疾病等基础疾病。共纳入有效方剂146首,涉及59个处方、115味中药。对146首方剂进行频数分析显示,COVID-19患者常用方剂为清肺排毒汤(30次,20.55%)、宣白承气汤(10次,6.85%)、大元饮(10次,6.85%)。常用中药为甘草(80次,54.79%)、茯苓(76次,52.05%)、石膏(70次,47.95%)、苦杏仁(70次,47.95%)、麻黄(57次,39.04%)、黄芩(5次,38.36%)、陈皮(53次,36.30%)、广藿香(50次,34.25%)、白术(50次,34.25%)、柴胡(43次,29.45%)。主要功效为清热解毒(129次)、清热泻火(129次)、利湿利尿(110次)。药性以温(509次)、平(287次)、寒(235次)为主。药味以辛(765次)、甘(654次)、苦(626次)为主。归经以肺(1096次)、脾(785次)、胃(687次)为主。相关性分析显示,共有17组药物组合,其中支持度排名前3的药对为苦杏仁 - 石膏(0.43)、麻黄 - 苦杏仁(0.38)、陈皮 - 茯苓(0.36)、麻黄 - 石膏(0.36)。聚类分析显示有3组聚类方。第一组为麻黄、苦杏仁、石膏。第二组为广藿香、茯苓、陈皮、白术。第三组为黄芩、甘草、枳实、泽泻、柴胡、生姜、桂枝。核心药物由茯苓、柴胡、陈皮、白术、广藿香、苦杏仁、黄芩、石膏、麻黄、甘草组成。

结论

COVID-19中老年患者伴有正气亏虚、毒邪内侵,病机演变迅速。湿浊毒邪常阻滞肺脏、困遏脾胃,导致气机失调,甚至内陷营血,耗阴竭阳。治疗以祛浊解毒为主,扶正养阴为治本之法,使邪去正复。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验